Literature DB >> 26135327

Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique.

Myres Tilghman1, Daniel Tsai, Titos P Buene, Manuel Tomas, Salma Amade, Daniel Gehlbach, Stephanie Chang, Caroline Ignacio, Gemma Caballero, Stephen Espitia, Susanne May, Emilia V Noormahomed, Davey M Smith.   

Abstract

BACKGROUND: In resource-limited settings, viral load monitoring of HIV-infected patients receiving antiretroviral therapy (ART) is not readily available because of high costs. Here, we compared the accuracy and costs of quantitative and qualitative pooled methods with standard viral load testing.
METHODS: Blood was collected prospectively from 461 patients receiving first-line ART in Mozambique who had not been evaluated previously with viral load testing. Screening for virologic failure of ART was performed quantitatively (ie, standard viral loads) and qualitatively [one and 2 rounds of polymerase chain reaction (PCR)]. Individual samples and minipools of 5 samples were then analyzed using both methods. The relative efficiency, accuracy, and costs of each method were calculated based on viral load thresholds for ART failure.
RESULTS: Standard viral load testing of individual samples revealed a high rate of ART failure (19%-23%) across all virologic failure thresholds, and the majority of the patients (93%) with viral loads >1500 copies per milliliter had genotypic resistance to drugs in their ART regimen. Pooled quantitative screening and deconvolution testing had positive and negative predictive values exceeding 95% with cost savings of $11,250 compared with quantitative testing of each sample individually. Pooled qualitative screening and deconvolution testing had a higher cost savings of $30,147 for 1 PCR round and $25,535 for 2 PCR rounds compared with quantitative testing each sample individually. Both pooled qualitative PCR methods had positive and negative predictive values ≥90%, but the pooled 1-round PCR method had a sensitivity of 64%.
CONCLUSIONS: Given the high rate of undiagnosed ART failure and drug resistance in this cohort, it is clear that virologic monitoring is urgently needed in this population. Here, we compared alternative methods of virologic monitoring with standard viral load testing of individual samples and found these methods to be cost saving and accurate. The test characteristics of each method will likely need to be considered for each local population before it is adopted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26135327      PMCID: PMC4607635          DOI: 10.1097/QAI.0000000000000724

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  17 in total

1.  Viral load testing in resource-limited settings.

Authors:  Robert T Schooley
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

2.  Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.

Authors:  G U van Zyl; W Preiser; S Potschka; A T Lundershausen; R Haubrich; D Smith
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

3.  Running with scissors: using antiretroviral therapy without monitoring viral load.

Authors:  Davey M Smith; Robert T Schooley
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

4.  Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico.

Authors:  Myres W Tilghman; Don Diego Guerena; Alexei Licea; Josué Pérez-Santiago; Douglas D Richman; Susanne May; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

5.  HIV viral load monitoring in resource-limited regions: optional or necessary?

Authors:  Alexandra Calmy; Nathan Ford; Bernard Hirschel; Steven J Reynolds; Lut Lynen; Eric Goemaere; Felipe Garcia de la Vega; Luc Perrin; William Rodriguez
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

Review 6.  Patient needs and point-of-care requirements for HIV load testing in resource-limited settings.

Authors:  Martine Usdin; Martine Guillerm; Alexandra Calmy
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

7.  Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

Authors:  Susanne May; Anthony Gamst; Richard Haubrich; Constance Benson; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

8.  The use of pooled viral load testing to identify antiretroviral treatment failure.

Authors:  Davey M Smith; Susanne J May; Josué Pérez-Santiago; Matthew C Strain; Caroline C Ignacio; Richard H Haubrich; Douglas D Richman; Constance A Benson; Susan J Little
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

9.  HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand.

Authors:  David Wilson; A Kace Keiluhu; Suphawadee Kogrum; Tony Reid; Noppadol Seriratana; Nathan Ford; Moe Kyawkyaw; Phol Talangsri; Nattayapa Taochalee
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12-24       Impact factor: 2.184

10.  A combined screening platform for HIV treatment failure and resistance.

Authors:  Myres W Tilghman; Susanne May; Josué Pérez-Santiago; Caroline C Ignacio; Susan J Little; Douglas D Richman; Davey M Smith
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more
  10 in total

1.  Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.

Authors:  T R Dinesha; J Boobalan; S Sivamalar; D Subashini; S S Solomon; K G Murugavel; P Balakrishnan; D M Smith; S Saravanan
Journal:  J Viral Hepat       Date:  2018-02-19       Impact factor: 3.728

2.  Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

Authors:  Alberto M La Rosa; Linda J Harrison; Babafemi Taiwo; Carole L Wallis; Lu Zheng; Peter Kim; Nagalingeswaran Kumarasamy; Mina C Hosseinipour; Bernadette Jarocki; John W Mellors; Ann C Collier
Journal:  Lancet HIV       Date:  2016-04-18       Impact factor: 12.767

3.  Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution.

Authors:  Tao Liu; Joseph W Hogan; Michael J Daniels; Mia Coetzer; Yizhen Xu; Gerald Bove; Allison K DeLong; Lauren Ledingham; Millicent Orido; Lameck Diero; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

4.  The objective function controversy for group testing: Much ado about nothing?

Authors:  Brianna D Hitt; Christopher R Bilder; Joshua M Tebbs; Christopher S McMahan
Journal:  Stat Med       Date:  2019-08-30       Impact factor: 2.373

5.  The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.

Authors:  Emily P Hyle; Ilesh V Jani; Katherine L Rosettie; Robin Wood; Benjamin Osher; Stephen Resch; Pamela P Pei; Paolo Maggiore; Kenneth A Freedberg; Trevor Peter; Robert A Parker; Rochelle P Walensky
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

6.  Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.

Authors:  Kenneth A Freedberg; Nagalingeswaran Kumarasamy; Ethan D Borre; Eric L Ross; Kenneth H Mayer; Elena Losina; Soumya Swaminathan; Timothy P Flanigan; Rochelle P Walensky
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-03       Impact factor: 1.723

7.  Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.

Authors:  Marta Iglis Oliveira; Valter Romão de Souza Junior; Claudia Fernanda de Lacerda Vidal; Paulo Sérgio Ramos de Araújo
Journal:  BMC Infect Dis       Date:  2018-10-12       Impact factor: 3.090

8.  Association of HIV/AIDS Clinician Warm Line Utilization with Diagnosis and Management of Antiretroviral Treatment Failure in Mozambique: A Retrospective Analysis of Program Data.

Authors:  Maria Ruano Camps; Paula E Brentlinger; Gerito Augusto; Alexandre Nguimfack; Florindo Mudender
Journal:  J Int Assoc Provid AIDS Care       Date:  2017-05-31

9.  Interferon-γ-Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings.

Authors:  Lucía Pastor; Aina Casellas; María Rupérez; Jorge Carrillo; Sonia Maculuve; Chenjerai Jairoce; Roger Paredes; Julià Blanco; Denise Naniche
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

Review 10.  Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring.

Authors:  Wolfgang Preiser; Gert U van Zyl
Journal:  Afr J Lab Med       Date:  2020-08-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.